US92840H2022
© BusinessWire
26.11.2025
VTGN
LISTED
NASDAQ
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
VTGN
LISTED
NASDAQ
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate upd...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
VTGN
LISTED
NASDAQ
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
05.11.2025
VTGN
LISTED
NASDAQ
Vistagen to Participate in Stifel Healthcare Conference 2025
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at th...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
VTGN
LISTED
NASDAQ
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
VTGN
LISTED
NASDAQ
Vistagen Appoints Paul Edick to its Board of Directors
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors (“Board”). Following the appointment of Mr. Edick,...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at The Menopause Society 2025 Annual Meeting
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Mee...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5t...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
VTGN
LISTED
NASDAQ
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Ea...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at the BTIG Virtual Biotechnology Conference
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtua...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
VTGN
LISTED
NASDAQ
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-dri...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
VTGN
LISTED
NASDAQ
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the eva...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.06.2025
VTGN
LISTED
NASDAQ
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update.
“This was a defin...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
VTGN
LISTED
NASDAQ
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. East...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
VTGN
LISTED
NASDAQ
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Pro...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York.
Vistagen’s President and Chief...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
VTGN
LISTED
NASDAQ
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in L...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
VTGN
LISTED
NASDAQ
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from Apr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
VTGN
LISTED
NASDAQ
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel’s 2025 Virtual CNS Forum.
Vistagen’s President and Chief Executive Offi...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
VTGN
LISTED
NASDAQ
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference.
Vistagen’s President and Chief Executive Officer, Shawn Singh, will...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
VTGN
LISTED
NASDAQ
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update....
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
VTGN
LISTED
NASDAQ
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Easte...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
VTGN
LISTED
NASDAQ
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
News Preview
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
VTGN
LISTED
NASDAQ
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the loss of appetite assoc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
VTGN
LISTED
NASDAQ
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD)....
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
VTGN
LISTED
NASDAQ
Vistagen to Present at the Stifel 2024 Healthcare Conference
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City.
Stifel 2024 Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
VTGN
LISTED
NASDAQ
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update.
“We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
VTGN
LISTED
NASDAQ
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registratio...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
VTGN
LISTED
NASDAQ
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
News Preview
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30,...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
VTGN
LISTED
NASDAQ
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation’s MindUP, a neuroscience-based preventative mental health program for youth, along with children from...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
VTGN
LISTED
NASDAQ
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
News Preview
Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
VTGN
LISTED
NASDAQ
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
News Preview
Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 first quarter ended June 30, 2024, a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
